BIA reaction to UK’s Autumn Budget 2025

The UK BioIndustry Association (BIA) has welcomed key measures in yesterday’s Autumn Budget that that broadly support the growth of life science and biotech scale-ups, while flagging concerns over rising costs for laboratory space.

The Budget did not contain any specific moves to affect the biotech or pharma industries, but some of its wider taxation proposals are likely to impact these sectors, which the BIA has identified.

Commenting on the Chancellor's Autumn Budget 2025, Jane Wall, managing director of the UK BioIndustry Association, said: "BIA has long argued that outdated limits on venture investment tax incentives and employee share options are holding back the scale-up of life science companies, so we are delighted that the Chancellor has chosen to extend these today. Ahead of the Budget, the CEOs of 200 of our member companies wrote to the Chancellor calling for these changes, so we are pleased to see that noted and delivered.